Wednesday, November 18, 2026

Sam Chun Dang Pharm. Expands Apotex Deal from a Single Product to a Portfolio, Adding New Macular Degeneration Treatment

Input
2026-10-01 17:09:24
Updated
2026-10-01 17:09:24
Provided by Sam Chun Dang Pharm.

[Financial News]  Sam Chun Dang Pharm. is expanding its macular degeneration treatment business with Canadian partner Apotex from a single biosimilar to a portfolio of multiple products. Following the commercialization of its existing Eylea biosimilar, SCD411, in Canada, the company is adding new macular degeneration treatments and expanding its product lineup through its existing overseas sales networks.
According to an electronic filing with the Financial Supervisory Service on the 1st, Sam Chun Dang Pharm. added new products to its supply agreement with Apotex for macular degeneration treatments. The product names, contract amount, milestones and profit-sharing terms were not disclosed under a confidentiality clause. The disclosure deferral deadline is October 1, 2036.
The key point of the agreement is that the partnership with Apotex has expanded from supplying the single product SCD411 to multiple ophthalmic products. Rather than developing new markets, the arrangement adds products to sales networks already secured in Canada and six Middle Eastern countries.
In 2023, Sam Chun Dang Pharm. signed an exclusive supply and sales agreement with Apotex for SCD411 vials and prefilled syringes (PFS) in Canada. The contract was valued at $15 million, or approximately KRW 20 billion at the time. After sales begin, Sam Chun Dang Pharm. will receive 25% to 50% of net profit, depending on the timing of insurance coverage and other factors.
SCD411 has received approval in Canada and entered the sales stage. In February this year, the collaboration region was expanded to six Middle Eastern countries, including Saudi Arabia.
Meanwhile, some of the contract terms for the new products differ from those for SCD411. Under the existing agreement, even if the contract was terminated because of failure to obtain approval or other reasons, there was no obligation to return milestones already received or pay a penalty. For the new products, however, a termination fee may be imposed, up to the amount of milestones already received, if the contract is terminated for certain reasons.
A bio industry source said, "Adding follow-up products to an existing overseas sales network can reduce the burden of rebuilding distribution infrastructure. Since the new products have not been disclosed, their actual business value will need to be assessed after reviewing the future approval stages and contract size." 


[email protected] Kim Kyung-ah Reporter